$MDT

Generating a unique summary for MDT…

AI-generated for information only — not investment advice.

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients in the United States, Ireland, and internationally. It operates through three segments: The Cardiovascular Portfolio, Neuroscience Portfolio, and Medical Surgical Portfolio. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves, left atrial appendage exclusion systems, extracorporeal membrane oxygenation (ECMO) systems and percutaneous coronary intervention products, percutaneous angioplasty balloons, and endovenous products. The Neuroscience Portfolio segment offers medical devices and implants, biologic solutions, spinal cord stimulation and brain modulation systems, implantable drug infusion systems, and interventional products, as well as nerve ablation system under the Accurian name. This segment offers its products for spinal surgeons, neurosurgeons, neurologists, pain management specialists, anesthesiologists, orthopedic surgeons, urologists, urogynecologists, and interventional radiologists, as well as ear, nose, and throat specialists, and energy surgical instruments. The Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure and electrosurgery products, AI-powered surgical video and analytics platform, robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology products, gastrointestinal and hepatologic diagnostics and therapies, and therapies to treat diseases and conditions, and patient monitoring and airway management products, as well as insulin pumps and consumables, continuous glucose monitoring systems, and sensors. Medtronic plc was founded in 1949 and is headquartered in Galway, Ireland.

Institutions hold 88.76% · insiders 0.39% · 2,911 institutions

Consensus score 1.72 (1 = strong buy, 5 = sell) · mean target 104.76

• UBSBuymain2026-09-03
• Truist SecuritiesHoldreit2026-09-02
• Wells FargoOverweightmain2026-09-02
• RBC CapitalOutperformreit2026-09-02
• B of A SecuritiesBuymain2026-09-02
• StifelHoldmain2026-09-02
• BairdNeutralmain2026-09-02
• BTIGBuymain2026-09-01
• NeedhamBuyreit2026-09-01
• TD CowenBuymain2026-08-28

Next report: 2026-11-17

• 10-QPeriodic Financial Reports2026-09-03Open
• 8-KCorporate Changes & Voting Matters2026-09-01Open
• ARSAnnual Report to Shareholders2026-08-24Open
• DEF 14AProxy Statements2026-08-17Open
• IRANNOTICENotice of disclosure filed in Exchange Act quarterly and annual reports pursuant to Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 and Section 13(r) of the Exchange Act2026-06-18Open
• 8-KCorporate Changes & Voting Matters2026-06-03Open
• SDSpecialized Disclosure Report filed pursuant to Section 1502 of the Dodd-Frank Wall Street Reform and Consumer Protection Act relating to the use of conflict minerals (Rule 13p-1)2026-05-28Open
• 8-KCorporate Changes & Voting Matters2026-05-18Open
• 8-KCorporate Changes & Voting Matters2026-04-27Open
• 8-KCorporate Changes & Voting Matters2026-03-24Open

• Medtronic executives to speak at upcoming investor conferences

  Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced it will participate in the following investor conferences:

  Fri, 04 Sep 2026 16:34:00 +0000

• 4 Reasons to Buy Medtronic Stock Like There's No Tomorrow

  The medical device maker is on the cusp of a multi-year recovery.

  Thu, 03 Sep 2026 16:25:00 +0000

• Is Medtronic Stock Underperforming the Dow?

  While Medtronic has outperformed relative to the Dow over the past three months, Wall Street analysts maintain a cautiously optimistic outlook on the stock’s prospects.

  Wed, 02 Sep 2026 16:00:24 +0000

• Medtronic Begins Fiscal 2027 With a Beat-and-Raise, Validating Growth Acceleration, RBC Says

  Medtronic (MDT) delivered a broad-based beat-and-raise to begin fiscal 2027, marking a defining step

  Wed, 02 Sep 2026 15:25:16 +0000

• MDT Q1 Earnings Call Focuses on Broad Growth, Raised Guidance

  Medtronic raises its fiscal 2027 outlook as growth broadens across major franchises and newer platforms, with robotics and ablation investments advancing.

  Wed, 02 Sep 2026 14:00:00 +0000

• Medtronic raises FY27 outlook after reporting strong Q1 growth

  Medtronic’s cardiac ablation solutions, a sub-segment of its electrophysiology business, was the strongest performer in Q1 with YoY growth of 29.5%.

  Wed, 02 Sep 2026 11:04:48 +0000

• Global Surgical Robots Market to Reach $10.6 Billion in 2026, Driven by AI Integration and Minimally Invasive Surgery

  Report Features In-Depth Profiles of Abbott, Great Robotics, Intuitive Surgical, Johnson & Johnson, Medtronic, Panasonic, Renishaw, Siemens Healthineers, Smith+Nephew, Stryker, Zimmer Biomet, and FreehandDublin, Sept. 07, 2026 (GLOBE NEWSWIRE) -- The "Surgical Robots Market by Offering of Surgical Robot Developers, Deployment Model, Type of Surgical Procedure Supported, Application Area, End Users and Key Geographical Regions - Trends and Forecast Till 2035" has been added to ResearchAndMarkets.

  Mon, 07 Sep 2026 08:21:00 +0000

• Should Investors Buy SOLV as Growth Improves but Debt Risks Persist?

  Solventum's growth, higher earnings outlook and cost cuts strengthen its case, but heavy debt and 2027 margin risks temper the upside.

  Wed, 02 Sep 2026 17:54:00 +0000